Inoviem Scientific, a subsidiary of Hybrigenics, takes over Bcell Design and its subsidiary Arkab

Thanks to this acquisition, Inoviem Scientific is opening a complementary avenue through the upstream development of immunoglobulin production for the fight against cancers and chronic inflammatory diseases.

Indeed, Bcell Design’s technologies, capable of developing immunoglobulins, combined with the technologies for identifying therapeutic targets and stratifying patients developed by Inoviem Scientific, will position the group as the only player capable of significantly accelerating the clinical development of therapeutic compounds for the treatment of patients.

Download Hybrigenics press release:

Need Help